Predicting response to iron supplementation in patients with active inflammatory bowel disease (PRIme): a randomised trial protocol
Introduction Iron deficiency anaemia (IDA) is the most common systemic manifestation of inflammatory bowel disease (IBD) that has detrimental effects on quality of life (QoL) and disease outcomes. Iron deficiency (ID), with or without anaemia, poses a diagnostic and therapeutic challenge in patients...
Saved in:
| Main Authors: | Andrea E van der Meulen-de Jong, Gerard Dijkstra, Zlatan Mujagic, Marjolijn Duijvestein, Rogier L Goetgebuer, Roberta Loveikyte |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2024-01-01
|
| Series: | BMJ Open |
| Online Access: | https://bmjopen.bmj.com/content/14/1/e077511.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Iron Deficiency Anemia in Inflammatory Bowel Disease
by: Izabela Dzikowska, et al.
Published: (2025-04-01) -
Environmental footprint of a colonoscopy procedure: Life cycle assessment
by: Paulina Lämmer, et al.
Published: (2025-01-01) -
Iron deficiency and fatigue in inflammatory bowel disease: A systematic review.
by: Stephanie Sartain, et al.
Published: (2025-01-01) -
The Effect of Intravenous Iron Treatment on Quality of Life in Inflammatory Bowel Disease Patients with Nonanemic Iron Deficiency
by: Cem Çekiç, et al.
Published: (2015-01-01) -
Perspectives on Treatment of Inflammatory Bowel Disease in Older Patients: Applying Gut-Feeling in an Evidence-Based Era?
by: Vera E.R. Asscher, et al.
Published: (2022-05-01)